1H25 Investor Presentation Materials
Released
Released
Announcement PDF
1H26 Investor Briefing | Page 1
ASX Announcement
19 February 2026
1H25 Investor Presentation Materials
Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial results
for the half-year ended 31 December 2025 (1H26) and also provides commentary in respect of the business and
financial outlook.
The presentation material is attached to this announcement.
Investors are invited to join a live webcast and Q&A hosted by Brad O’Connor, CEO, Darren Watson, CFO and
Rachel Colite Executive Vice President, Clinical Trials on Thursday 19 February 2026 at 9:30am Australian Eastern
Daylight Savings Time.
Please register at: https://investors.cogstate.com/webinars/8r67wP-cogstate-h12026-financial-results
Additionally, a video recording of the presentation will be available on demand following the presentation at the
Cogstate Investor Centre homepage: https://investors.cogstate.com.
This announcement was authorised for release by a sub-committee of the Board of Cogstate Ltd. For further
information contact: investor@cogstate.com
FY24 Investor Briefing | Page 2
About Cogstate
Cogstate Ltd (ASX: CGS) is a global Central Nervous System (CNS) endpoint innovations company that partners
with drug developers to power complex neuroscience studies. Cogstate uniquely specializes in the science and
service of CNS measurement to ensure clinical trial endpoint data is as accurate as it is actionable. Our applied
technology solutions include fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing
to identify clear signals for confident decision-making. Building upon 25 years of customized collaborations,
Cogstate is accelerating the next generation of CNS therapies. In the Healthcare market, Cogstate seeks to provide
primary care physicians and consumers with brief, accurate and scientifically validated digital measures of
cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For
more information, please visit www.cogstate.com.
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of
Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied
upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in
this announcement, nor any information made available to you is, or shall be relied upon as, a promise, representation,
warranty or guarantee, whether as to the past, present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”,
“intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position
and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided
in this announcement are based on assumptions and contingencies that are subject to change without notice and
involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its
directors and management. Forward-looking statements are provided as a general guide only and should not be
relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such
statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be
realised in the period for which the forward-looking statement may have been prepared or otherwise. For example,
Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period,
or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by factors that are
outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or
regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forward-
looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this announcement. The forward-looking statements are based on information available to Cogstate as
at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of
Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information,
whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.
Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-
looking statements.
© 2026 Cogstate Ltd. All rights reserved.
Investor Presentation
1H26 Financial Results
19 February 2026
Brad O’Connor, CEO | Darren Watson, CFO | Rachel Colite, EVP Clinical Trials
2
2
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general
nature and does not purport to be complete, nor does it contain all the information which would be required in a prospectus
prepared in accordance with the requirements of the Corporations Act. This presentation may contain statements, opinions,
projections, forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may
or may not prove to be correct. None of Cogstate, its respective officers, employees, agents, advisers or any other person
named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of any forward looking
statements or any of the assumptions upon which they are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or
particular needs of any recipient and is not financial product advice. Before making an investment decision, recipients of this
presentation should consider their own needs and situation and, if necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty,
representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation.
Further, none of Cogstate and its respective officers, employees, agents and advisers accept, to the extent permitted by law,
responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, the information contained in
this presentation. Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information
contained herein.
3
1H26 Business Highlights
Expansion and diversification of trial
portfolio and customer base
1
• 133 ongoing trials at 31 Dec 2025 -
up 34% year-on-year.
• 42 new trial starts in 1H26.
• 6× growth in sales to mood, sleep and
other neurological disorder programs
validating resource investment.
• New pharma and large-biotech
customers added, each with potential
for multi-program pipelines.
Channel partnerships gaining
momentum
2
• Record number of sales opportunities
identified in each of the past six
quarters.
• In the Dec-25 quarter, channel
partners drove 70% of opportunities
and 62% of executed sales contracts.
• No margin impact from co-selling
through partners.
Technology advancement
3
• Ongoing progress and customer
uptake in Cogstate’s proprietary AI-
powered solutions.
4
1H26 Financial Highlights
Growing market
share in an
expanding market
1
Sales up 105%, driven
by record opportunities
from an expanded,
more diversified
customer base across
multiple indications.
CNS expected to be
one of the fastest
growing R&D areas.
1H26 revenue $26.9m
is up 12% vs pcp
License fees 23% of
Clinical Trials revenue
- up from 19% pcp
- down from 31% in
2H25
License fee revenue
generally recorded
when contract
executed.
2
Cost of sales has
increased, but with
some qualification
17% increase in
Clinical Trials delivery
staff to support a
larger, more diversified
portfolio.
Reallocation of costs
and one-off items
impacted 1H26
results.
3
Temporary margin
impact will enable
sales growth
EBITDA $6.5m at
24.3% margin
Profit before tax of
$5.3m at 19.8%
margin.
Profit after tax of
$4.5m at 16.7%
margin.
4
Forecasting revenue
and profit growth in
2H26
$21.7m contracted
revenue for 2H26
- up 24% vs pcp
$27.0m contracted
revenue for FY27
- Up 13% vs pcp
Sales pipeline remains
at record level.
5
All figures in US$
5
Financial Summary - Operational Leverage Evident
Key Points:
• Revenue up 12% with OpEx down 9%.
• Operating costs declining as % of revenue as business scales.
• Gross Margin: 52.8% vs 61.4% pcp
- Gross margin compression temporary, market share
gains enduring.
- Strategic reallocation of senior scientists to delivery
supports entry into high-value mood disorder markets.
- FTE investment (+13.1 delivery staff) underpinning 6x
growth in mood/sleep contracts.
- Doubtful debt provision: $0.5M (non-recurring)
• 2H26 margin recovery: 56-59%. Long-term target: 60%+.
• Technology Investment
- D&A up 16% from AI tools and platform development,
with capitalised software spend of $2.8M (vs $0.7M pcp).
1H26 1H25 Movement
Total Revenue $26.9M $23.9M Up 12%
Gross Profit $14.2M $14.7M Down 3%
Gross Margin 52.8% 61.4%
Down
8.6 points
Operating Costs ($7.7M) ($8.5M) Down 9%
EBITDA $6.5M $6.2M Up 5%
EBITDA Margin 24.3% 26.0%
Down
1.7 points
Net Profit (before tax) $5.3M $5.2M Up 2%
NPBT Margin 19.8% 21.8%
Down
2 points
Net Profit (after tax) $4.5M $3.9M Up 16%
NPAT Margin 16.7% 16.3% Up 0.4 points
6
Maturation of Revenue Profile Enabling Growth
Highlights
• Increase in Clinical Trials sales contracts.
• License fees 23% of Clinical Trials revenue.
- Higher mix of full-service endpoint solutions.
- Multi-year revenue durability.
• Run-off of a strong, diversified contracted revenue
backlog (by indication, phase and customer).
• Healthcare revenue under the Eisai agreement
provides a stable, high-margin recurring base, albeit
a modest share of Group revenue.
1H26 2H25 1H25
Total Revenue $26.9m $29.1m $23.9m
- Clinical Trials Revenue $25.7m $27.9m $22.7m
- Healthcare Revenue $1.2m $1.3m $1.2m
7
Revenue Performance of Clinical Trials
6
11
16
21
26
31
1H20 2H20 1H21 2H21 1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26
US$
Million
1H26 Clinical Trials Revenue $25.7m
• 13% growth against pcp; down compared to most
recent half-year
- Half-to-half variability normal due to milestone-
based revenue recognition.
• License fee revenue 23% of Clinical Trials revenue
- 19% in 1H25.
- 31% in 2H25.
• Improved durability of revenue supporting more
predictable forecasting.
• Contracted revenue of $21.7M for 2H26 (up 24%)
demonstrates strong trajectory continuing.
8
Cost of Sales
Key Items Impacting 1H26:
Planned investment to support growth:
• 17% increase in direct staff in Clinical Trials (excl.
BD) to manage larger, more varied portfolio of
work. 89.8 FTE at 31-Dec-25 .
Share based payment expense:
• Benefit recorded in 1H25 from LTI that did not
vest. Note that 2H25 expense was $0.4m.
Other costs & reallocations:
• $0.8m reallocation of science resources from
operating expenses to cost of sales (no bottom-
line impact).
• $0.2m Increase in business development
commissions due to higher sales (will flex with
sales achieved each half).
• $0.5m Provision for doubtful debt from US based
biotech (shown in other direct costs).
US$ millions 1H26 1H25 Change
Direct wages and salaries 9.4 7.2 2.2
Less capitalization of software development costs (0.4) (0.2) (0.2)
Share based payment expense 0.5 0.1 0.4
Direct contractor 1.8 1.6 0.2
Direct depreciation 0.1 0.1 0.0
Other direct costs 1.4 0.6 0.8
Cost of Sales 12.8 9.4 3.4
Net result: Excluding “Other costs & reallocations”, pro-
forma gross margin was 58.4%, within expected margin range
given investment in resources to support growth.
9
Strong Cash Position Supports Growth Investment
Key Points:
• $34.1M cash, no debt,
• Operating cashflow: Tax paid: +$2.2M
(reflects higher profitability).
• Investing cashflow: Technology capex:
+$2.2M (AI tools positioning for future).
• Financing cashflow:
- Options exercised: $0.7M additional
cash received in 1H26.
- Maiden dividend: $2.2M additional
outflow (shareholder return) in 1H26.
- Share buyback: $0.8M less spent on
share buy-back in 1H26.
Net result: Strong balance sheet with cash
actively deployed into growth and shareholder
returns.
US$ millions 1H26 1H25 Change
Net Profit after Tax 4.5 3.9 0.6
Depreciation & Amortization 1.6 1.4 0.2
Non-cash employee benefits 0.9 (0.1) 1.0
Grant funding received (0.1) (0.1) 0.0
Other (0.4) (0.4) 0.0
Change in working capital (4.1) 0.3 (4.4)
Operating Cash Flow 2.4 5.0 (2.6)
Cash Flow used in investing activities (2.7) (0.5) (2.2)
Cash flow used in Financing activities (1.2) (0.4) (0.8)
Total Cash Flow (1.5) 4.1 (5.6)
10
Contracted Future Revenue Provides Earnings Visibility
Actual 1H25 Revenue
Contracted Future Clinical
Trials Revenue
Contracted Future
Healthcare Revenue
Key Points:
• $104.9m contracted future revenue, up 6% vs PCP
- $92.3m Clinical Trials.
- $12.5m Healthcare.
• $48.6m in contracted FY26 revenue, up 17%
- $41.3m PCP.
- $21.7m 2H25 (vs $17.5m PCP).
26.9
20.5
24.7 22.9
14.7
9.5
1.1
2.3
2.3
2.3
4.5
0
10
20
30
40
50
60
FY26 FY27 FY28 FY29 FY30+
US$
Millions
Contracted Revenue
31-Dec-25
US$ 'm
31-Dec-24
US$ 'm
Change
US$ 'm
%
Next half 21.7 17.5 4.2 24%
Following FY 27.0 23.8 3.2 13%
FY+2 25.2 18.9 6.3 33%
FY+3 16.9 15.5 1.4 9%
FY+4 (and later) 14.1 23.5 (9.4) (40%)
Total 104.9 99.2 5.7 6%
11
Technology Investment and Status
Key Points:
• AI-powered Monitoring and Rater Training
progressing into development across additional
scales and languages.
• Platform transformation ~75% complete, delivering
standardisation, greater scalability, better integration
and stronger security.
• Algorithmic Monitoring gives customers deeper
insight into data quality for central monitoring.
• Data Reporting Enhancements improve visibility of
study status and progress, lifting internal efficiency.
US$ millions 1H26
AI-Powered Monitoring 0.4
AI-Powered Rater Training 0.1
Platform Transformation (Modernisation) 1.0
Algorithmic Monitoring 0.3
Data Reporting Enhancements 0.3
Other 0.7
Total 2.8
12
Sales Contracts Reflecting Greater Diversification
0
10
20
30
40
50
60
1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26
US$
Millions
1H26: $41.7m sales contracts executed
• 38% Alzheimer’s.
• 45% Mood, Sleep & Other Neurology.
• 15% Rare Diseases.
• 2% Cancer, Metabolic and Other Diseases.
2nd best half year ever recorded
• 2nd only to 1H22 $54.5m.
• 1H22 highly concentrated – 89% Alzheimer’s.
Alzheimer’s
Mood, Sleep & Other
Neurological
Rare
Cancer Metabolic &
Other
13
Pipeline Expansion Tracking to Sales Conversion
0
10
20
30
40
50
60
70
80
90
1QFY16
2QFY16
3QFY16
4QFY16
1QFY17
2QFY17
3QFY17
4QFY17
1QFY18
2QFY18
3QFY18
4QFY18
1QFY19
2QFY19
3QFY19
4QFY19
1QFY20
2QFY20
3QFY20
4QFY20
1QFY21
2QFY21
3QFY21
4QFY21
1QFY22
2QFY22
3QFY22
4QFY22
1QFY23
2QFY23
3QFY23
4QFY23
1QFY24
2QFY24
3QFY24
4QFY24
1QFY25
2QFY25
3QFY25
4QFY25
1QFY26
2QFY26
Number of New Opportunities Number of New Contracts
14
Expanding Portfolio of Clinical Trial Projects
1H26: 42 new trial starts (vs 25 pcp)
• 10% Alzheimer’s.
• 52% Mood, Sleep & Other Neurology.
• 36% Rare Diseases.
• 2% Cancer, Metabolic and Other Diseases.
Most active half year for new trial starts
• More than all FY25.
133 Total Active Trials Ongoing (vs 99 pcp)
• 31 Phase 3 trials (vs 21).
• 59 Phase 2 trials (vs 43).
• 24 Phase 1 trials (unchanged).
• 19 other (vs 11).
Alzheimer’s
Mood, Sleep & Other
Neurological
Rare
Cancer Metabolic &
Other
0
5
10
15
20
25
30
35
40
45
1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26
Number
of
Trials
Number Of New Trial Starts, per half
Team is ready for growth
• Expanded to manage a larger, more diversified
portfolio.
• Expect to see continued trial starts in 2H26.
15
Operational Example: Deep Scientific Collaboration Building a
Scalable Partner Franchise
A top-5 pharmaceutical
sponsor* chose Cogstate
for an early-phase
program where scientific
collaboration was
mission-critical.
Cogstate embedded its
science and technology
into the sponsor’s
ecosystem, integrating
with established and
emerging eCOA partners
and delivery models.
Engagement has
expanded to multiple
late-stage programs
across Alzheimer’s,
related dementias,
movement disorders and
mood disorders with
several eCOA partners.
New contract awards
expected to grow
materially over coming
years as the relationship
scales across indications
and geographies.
* by 2024 R&D spend
16
Momentum Predicated on Multiple Growth Drivers
Growth across multiple
indications
• Scientific and operational
investment driving expansion into
mood disorders (progressed) and
dermatology, autoimmune,
hematology (emerging).
• Cogstate endpoints regularly
selected as primary/key secondary
outcomes in sleep/narcolepsy trials
(4 programs and growing).
• Rare disease trials growing as
successful programs move to late
phase.
• Strong position in pre-symptomatic
Alzheimer’s as R&D shifts toward
prevention.
Channel partnerships maturing
and beginning to impact sales
momentum
• Channel partnerships with Medidata
and other eCOA partners are
delivering a growing share of qualified
opportunities and contract wins from
segments we could not efficiently
reach through direct sales alone.
Favorable competitive dynamics
• Few players in full-service CNS
endpoint management
• High barriers to entry requiring
specialised regulatory expertise and
validated solutions.
17
Capital Allocation
• The Board has determined not to declare an
interim dividend for the half-year ended 31
December 2025.
• The Company maintains its annual dividend
policy and will consider a final dividend at year
end.
• Share buyback is ongoing and will be utilised
when valuation is compelling.
Capital Management Priorities
• Strategic growth initiatives: Targeting
opportunities that align with strategy, enhance
capabilities, and build long-term value.
• Investment in innovation: Funding product and
service development to drive growth and
competitiveness.
• Capital returns: Flexible share buybacks when
valuation is compelling.
• Sustainable dividends: Targeting annual dividend
payout ratio of 20% - 50% of NPAT, while
retaining sufficient capital for growth and
innovation.
17
18
Outlook
2H26 & FY26 Outlook
• Revenue: Continued growth
expected, FY26 to exceed FY25.
• Gross margin: Return to 56-59% in
2H26.
• Operating leverage: Continue
demonstrating cost discipline.
• Sales pipeline: At record levels.
• Trial portfolio: 133 trials provides
multi-year visibility.
Strategic Investments
• Scientific resources: Psychiatry &
mood disorders expansion.
• Data engineering: AI-powered
analytical tools.
• Channel partnerships: Expanding
market reach.
All delivering measurable commercial
results.
Market Opportunity
• CNS R&D spending: Fastest
growing segment.
• Cogstate positioned to win
>proportional share.
• Proven delivery on large Phase 3
trials.
• Expanding capabilities across
indications.
• Partner of choice for breakthrough
CNS therapies.
19
Summary
Cogstate delivered solid revenue
growth, strong sales momentum and
increased future revenue visibility,
underpinned by disciplined cost
control and a solid cash position.
Strong H1
performance
with
operational
leverage
Record
diversified
sales
contracts
Market share
gains from
competitors
Record
contracted
revenue at the
start of 2H26
133 active
trials
providing
multi-year
visibility
Well-
positioned for
continued
growth
Share your feedback
Discover